Quick Answer
Arcutis Biotherapeutics, Inc. reported Total Revenue of $376.07 million for fiscal year 2025.
Arcutis Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $376.07M +91.3% |
$196.54M +229.7% |
$59.61M +1517.1% |
$3.69M | — | — |
| Net Income | -$16.14M +88.5% |
-$140.04M +46.6% |
-$262.14M +15.8% |
-$311.46M -50.9% |
-$206.36M -52.1% |
-$135.68M -223.1% |
| Diluted EPS | -$0.13 +88.8% |
-$1.16 +69.3% |
-$3.78 +33.2% |
-$5.66 -35.4% |
-$4.18 -10.0% |
-$3.80 +83.3% |
| Total Assets | $432.97M +24.1% |
$348.89M +2.2% |
$341.37M -24.0% |
$449.27M +10.1% |
$408.15M +36.8% |
$298.27M +178.7% |
| Cash and Equivalents | — | — | — | $53.64M -44.4% |
$96.45M +48.2% |
$65.08M +2.8% |
| Long-Term Debt | $107.96M +0.7% |
$107.20M -46.9% |
$201.80M +2.0% |
$197.77M +173.4% |
$72.35M | $0.00 |
| Stockholders Equity | $189.48M +20.3% |
$157.54M +77.7% |
$88.67M -57.7% |
$209.58M -29.6% |
$297.68M +10.0% |
$270.62M +516.2% |
| R&D Expense | $77.05M +0.8% |
$76.42M -30.9% |
$110.58M -39.4% |
$182.44M +25.3% |
$145.56M +26.2% |
$115.31M +215.7% |
| Operating Income | -$12.23M +90.5% |
-$128.40M +46.7% |
-$241.10M +20.1% |
-$301.63M -46.0% |
-$206.53M -51.1% |
-$136.65M -216.8% |
| Shares Outstanding | 123.33M +4.7% |
117.85M +21.8% |
96.79M +58.6% |
61.04M +21.5% |
50.26M +16.0% |
43.34M +1943.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $99.22M | +121.7% | +21.7% |
| Net Income | September 30, 2025 | $7.41M | +117.8% | +146.6% |
| Diluted EPS | September 30, 2025 | $0.06 | +118.2% | +146.2% |
| Total Assets | September 30, 2025 | $370.98M | -15.2% | +5.3% |
| Cash and Equivalents | September 30, 2023 | $107.47M | +31.8% | +2.2% |
| Long-Term Debt | September 30, 2025 | $107.50M | +2.3% | +0.4% |
| Stockholders Equity | September 30, 2025 | $158.07M | +0.9% | +13.7% |
| R&D Expense | September 30, 2025 | $19.60M | +0.5% | +0.8% |
| Operating Income | September 30, 2025 | $8.53M | +121.8% | +158.4% |
| Shares Outstanding | September 30, 2025 | 120.29M | +2.8% | +0.4% |
- Arcutis Biotherapeutics, Inc. reported Total Revenue of $376.07 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +91.3% in Total Revenue compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Net Income of -$16.14 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +88.5% in Net Income compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Diluted EPS of $0.13 per share (loss) for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +88.8% in Diluted EPS compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Total Assets of $432.97 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +24.1% in Total Assets compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Cash and Equivalents of $53.64 million for fiscal year 2022.
- Arcutis Biotherapeutics, Inc. showed a decrease of -44.4% in Cash and Equivalents compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Long-Term Debt of $107.96 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +0.7% in Long-Term Debt compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Stockholders Equity of $189.48 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +20.3% in Stockholders Equity compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported R&D Expense of $77.05 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +0.8% in R&D Expense compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Operating Income of -$12.23 million for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +90.5% in Operating Income compared to the prior fiscal year.
- Arcutis Biotherapeutics, Inc. reported Shares Outstanding of 123.33 million shares for fiscal year 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +4.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: